<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2444-054X</journal-id>
<journal-title><![CDATA[Cirugía y cirujanos]]></journal-title>
<abbrev-journal-title><![CDATA[Cir. cir.]]></abbrev-journal-title>
<issn>2444-054X</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Cirugía A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2444-054X2022000400439</article-id>
<article-id pub-id-type="doi">10.24875/ciru.21000626</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Cellularity and its relation with capsular characteristics as an influencing factor for operative strategies of pleomorphic adenoma]]></article-title>
<article-title xml:lang="es"><![CDATA[La celularidad y su relación con las características capsulares como factor influyente en las estrategias operatorias del adenoma pleomorfo]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[Chun-Cheng]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[Che-Tong]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[Yun-Ho]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Far Eastern Memorial Hospital Department of Pediatric Dentistry ]]></institution>
<addr-line><![CDATA[Taipei ]]></addr-line>
<country>Taiwan</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Taipei Medical University Institute of Oral Medicine ]]></institution>
<addr-line><![CDATA[Taipei ]]></addr-line>
<country>Taiwan</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Taipei Medical University Hospital Division of Oral Pathology Department of Dentistry]]></institution>
<addr-line><![CDATA[Taipei ]]></addr-line>
<country>Taiwan</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2022</year>
</pub-date>
<volume>90</volume>
<numero>4</numero>
<fpage>439</fpage>
<lpage>446</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2444-054X2022000400439&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2444-054X2022000400439&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2444-054X2022000400439&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: This study investigates the relationship between cellularity and capsular characteristics of pleomorphic adenoma and its influence on operative strategies.  Material and methods: The capsular characteristics and clinical data of patients with pleomorphic adenomas were reviewed according to Seifert&#8217;s definition: (1) classic type with balanced amount of cells and stroma, (2) myxoid type with abundant ground substance, interspersed spindle cells, and (3) cellular type with predominance of ductal trabecular structures and little stroma. The immunoreactivity of cellular proliferation (Ki-67) was semi-quantitatively measured using immunohistochemistry. Variables were analyzed using Fisher&#8217;s test and one-way ANOVA, with (p &lt; 0.05) considered statistically significant.  Results: The duration of presence was associated with cellularity (p = 0.01). In terms of capsular characteristics, satellite nodules and positive resection margins were not related to cellularity, except for incomplete capsules (p = 0.03). There was no difference in the staining scores of Ki-67 (p = 0.12).  Conclusion: Lower cellularity reflects higher probability of an incomplete capsule, requiring more consideration for operative strategies to prevent recurrence.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Este estudio investiga la relación entre la celularidad y las características capsulares del adenoma pleomórfico y su influencia en las estrategias operativas.  Material y métodos: Se revisaron las características capsulares y los datos clínicos de los pacientes con adenomas pleomórficos según la definición de Seifert: 1) tipo clásico con cantidad equilibrada de células y estroma, 2) tipo mixoide con abundante sustancia fundamental, células fusiformes intercaladas y 3) tipo celular con predominio de estructuras trabeculares ductales y poco estroma. La inmunorreactividad de la proliferación celular (Ki-67) se midió semicuantitativamente usando inmunohistoquímica. Las variables se analizaron mediante la prueba de Fisher y ANOVA de una vía, considerándose significativo un valor de p inferior a 0.05.  Resultados: La duración de la presencia se asoció con la celularidad (p = 0.01). En cuanto a las características capsulares, los nódulos satélites y los márgenes de resección positivos no se relacionaron con la celularidad, a excepción de las cápsulas incompletas (p = 0.03). No hubo diferencia en las puntuaciones de tinción de Ki-67 (p = 0.12).  Conclusiones: La celularidad más baja refleja una mayor probabilidad de una cápsula incompleta, lo que requiere una mayor consideración de las estrategias quirúrgicas para prevenir la recurrencia.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Capsular characteristics]]></kwd>
<kwd lng="en"><![CDATA[Cellularity]]></kwd>
<kwd lng="en"><![CDATA[Ki-67]]></kwd>
<kwd lng="en"><![CDATA[Operative strategies]]></kwd>
<kwd lng="en"><![CDATA[Pleomorphic adenoma]]></kwd>
<kwd lng="es"><![CDATA[Características capsulares]]></kwd>
<kwd lng="es"><![CDATA[Celularidad]]></kwd>
<kwd lng="es"><![CDATA[Ki-67]]></kwd>
<kwd lng="es"><![CDATA[Estrategias operativas]]></kwd>
<kwd lng="es"><![CDATA[Adenoma pleomórfico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagao]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Oshiro]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[H Takahashi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nagai]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunohistochemical analysis of salivary gland tumors:application for surgical pathology practice]]></article-title>
<source><![CDATA[Acta Histochem Cytochem]]></source>
<year>2012</year>
<volume>45</volume>
<page-range>269-82</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suh]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Hah]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical manifestations of recurrent parotid pleomorphic adenoma]]></article-title>
<source><![CDATA[Clin Exp Otorhinolaryngol]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>193-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[McGurk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of salivary gland neoplasms in a defined UK population]]></article-title>
<source><![CDATA[Br J Oral Maxillofac Surg]]></source>
<year>2013</year>
<volume>51</volume>
<page-range>399-403</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andreasen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Therkildsen]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Bjørndal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Homøe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleomorphic adenoma of the parotid gland 1985-2010:a Danish nationwide study of incidence, recurrence rate, and malignant transformation]]></article-title>
<source><![CDATA[Head Neck]]></source>
<year>2016</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1364-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valstar]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[de Ridder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van]]></surname>
<given-names><![CDATA[den]]></given-names>
</name>
<name>
<surname><![CDATA[Broek]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Stuiver]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[van Dijk]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[van Velthuysen]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salivary gland pleomorphic adenoma in the Netherlands:a nationwide observational study of primary tumor incidencemalignant transformation recurrence and risk factors for recurrence]]></article-title>
<source><![CDATA[Oral Oncol]]></source>
<year>2017</year>
<volume>66</volume>
<page-range>93-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valstar]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Andreasen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bhairosing]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[McGurk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history of recurrent pleomorphic adenoma:implications on management]]></article-title>
<source><![CDATA[Head Neck]]></source>
<year>2020</year>
<volume>42</volume>
<page-range>2058-66</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knight]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ratnasingham]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metastasising pleomorphic adenoma:systematic review]]></article-title>
<source><![CDATA[Int J Surg]]></source>
<year>2015</year>
<volume>19</volume>
<page-range>137-45</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falcão]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Kataoka]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Diniz Jr]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Alves Jr]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anovel cell line derived from pleomorphic adenoma expresses MMP2, MMP9, TIMP1, TIMP2, and shows numeric chromosomal anomalies]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Laskawi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wahlers]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hemmerlein]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland]]></article-title>
<source><![CDATA[Histopathology]]></source>
<year>2004</year>
<volume>44</volume>
<page-range>222-31</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tachikawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas]]></article-title>
<source><![CDATA[Histopathology]]></source>
<year>2009</year>
<volume>55</volume>
<page-range>250-60</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adley]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Gleason]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[XJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stack]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer:high level expression in clear cell carcinoma]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2009</year>
<volume>112</volume>
<page-range>319-24</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ricci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bruzzese]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[DI Carlo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer]]></article-title>
<source><![CDATA[Oncol Lett]]></source>
<year>2015</year>
<volume>10</volume>
<page-range>2527-32</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roh]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between histopathology of pleomorphic adenoma in the parotid gland and recurrence after superficial parotidectomy]]></article-title>
<source><![CDATA[J Surg Oncol]]></source>
<year>2012</year>
<volume>106</volume>
<page-range>942-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glas]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Hollema]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nap]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Plukker]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2002</year>
<volume>94</volume>
<page-range>2211-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Driemel]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Maier]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kraft]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Haase]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hemmer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Flow cytometric DNA ploidy in salivary gland tumours]]></article-title>
<source><![CDATA[Oncol Rep]]></source>
<year>2005</year>
<volume>13</volume>
<page-range>161-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Obtulovicova]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Starek]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Salzman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kalis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ehrmann]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sicak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recurrent salivary pleomorphic adenoma shows increased immunohistologic expression of bcl-2 oncoprotein]]></article-title>
<source><![CDATA[Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub]]></source>
<year>2015</year>
<volume>159</volume>
<page-range>460-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naeim]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Forsberg]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Waisman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Coulson]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mixed tumors of the salivary glandsGrowth pattern and recurrence]]></article-title>
<source><![CDATA[Arch Pathol Lab Med]]></source>
<year>1976</year>
<volume>100</volume>
<page-range>271-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reshma]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Priya]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Umadevi]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Smitha]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sheethal]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of maspin in benign and malignant salivary gland tumors:an immunohistochemical study]]></article-title>
<source><![CDATA[Indian J Dent Res]]></source>
<year>2014</year>
<volume>25</volume>
<page-range>346-51</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seifert]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Langrock]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Donath]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A pathological classification of pleomorphic adenoma of the salivary glands (author's transl)]]></article-title>
<source><![CDATA[HNO]]></source>
<year>1976</year>
<volume>24</volume>
<page-range>415-26</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[OP]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kowalski]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleomorphic adenoma of the submandibular gland:clinicopathological and immunohistochemical features of 60 cases in Brazil]]></article-title>
<source><![CDATA[Arch Otolaryngol Head Neck Surg]]></source>
<year>2002</year>
<volume>128</volume>
<page-range>1400-3</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zbären]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Stauffer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleomorphic adenoma of the parotid gland:histopathologic analysis of the capsular characteristics of 218 tumors]]></article-title>
<source><![CDATA[Head Neck]]></source>
<year>2007</year>
<volume>29</volume>
<page-range>751-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paris]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Facon]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chrestian]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Giovanni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zanaret]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleomorphic adenoma of the parotid:histopathological study]]></article-title>
<source><![CDATA[Ann Otolaryngol Chir Cervicofac]]></source>
<year>2004</year>
<volume>121</volume>
<page-range>161-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Savera]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Zarbo]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Defining the role of myoepithelium in salivary gland neoplasia]]></article-title>
<source><![CDATA[Adv Anat Pathol]]></source>
<year>2004</year>
<volume>11</volume>
<page-range>69-85</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iro]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zenk]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Koch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Klintworth]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Follow-up of parotid pleomorphic adenomas treated by extracapsular dissection]]></article-title>
<source><![CDATA[Head Neck]]></source>
<year>2013</year>
<volume>35</volume>
<page-range>788-93</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sood]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McGurk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vaz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of salivary gland tumours:United Kingdom national multidisciplinary guidelines]]></article-title>
<source><![CDATA[J Laryngol Otol]]></source>
<year>2016</year>
<volume>130</volume>
<page-range>142-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[YQ]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[ZH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence for determining the safe surgical margin for pleomorphic adenoma of parotid gland]]></article-title>
<source><![CDATA[Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi]]></source>
<year>2012</year>
<volume>47</volume>
<page-range>137-41</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of new genes of pleomorphic adenoma]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2019</year>
<volume>98</volume>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leick]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Melssen]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Benamar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lindsay]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Eki]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The barrier molecules junction plakoglobin filaggrin and dystonin play roles in melanoma growth and angiogenesis]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>2019</year>
<volume>270</volume>
<page-range>712-22</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimbo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tanemura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yamazaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tamai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Katayama]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kaneda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2010</year>
<volume>5</volume>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumamoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Goto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sekikawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Takenoshita]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ishida]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kawakita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased expression of UDP-galactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2001</year>
<volume>61</volume>
<page-range>4620-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valstar]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Mast]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ten Hove]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Moonen]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Balm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smeele]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant transformation of salivary gland pleomorphic adenoma:proof of principle]]></article-title>
<source><![CDATA[J Pathol Clin Res]]></source>
<year>2021</year>
<volume>7</volume>
<page-range>432-7</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Langman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Weissferdt]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[WT1 expression in salivary gland pleomorphic adenomas:a reliable marker of the neoplastic myoepithelium]]></article-title>
<source><![CDATA[Mod Pathol]]></source>
<year>2011</year>
<volume>24</volume>
<page-range>168-74</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
